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ABSTRACT
The estrogen receptor-related receptor a (ERRa)i s
an orphan member of the nuclear receptor super-
family that has been shown to interfere with the
estrogen-signaling pathway. In this report, we
demonstrate that ERRa also cross-talks with signal-
ing driven by other steroid hormones. Treatment
of human prostatic cells with a specific ERRa
inverse agonist reduces the expression of several
androgen-responsive genes, in a manner that does
not involve perturbation of androgen receptor
expression or activity. Furthermore, ERRa activates
the expression of androgen response elements
(ARE)-containing promoters, such as that of the
prostate cancer marker PSA, in an ARE-dependent
manner. In addition, promoters containing a
steroid response element can be activated by all
members of the ERR orphan receptor subfamily,
and this, even in the presence of antisteroid
compounds.
INTRODUCTION
The estrogen receptor-related receptor a (ERRa)i sa
member of the nuclear receptor superfamily, that, together
with its paralog ERRb, has been identiﬁed due to
its high level of sequence identity with the estrogen recep-
tor a(ERa) (1). A third member of the subfamily, ERRg,
has also been isolated more recently (2). These three
receptors are referred to as ‘orphan’, since their transcrip-
tional activities do not require the addition of an
identiﬁed physiological ligand (3). Crystallographic stu-
dies have shown that apo-ERRa and apo-ERRg sponta-
neously adopt an active conformation, indicating that
they can activate transcription in a constitutive manner
(4,5). A speciﬁc, synthetic inverse agonist (XCT790) of
ERRa has however been identiﬁed that deactivates the
receptor (6) and induces its proteasome-dependent degra-
dation (7), thus facilitating the study of its activities, at
least in cell culture.
ERRb has been shown to be involved in the formation
of the placenta and to regulate the maturation of primor-
dial germ cells (8,9), whereas ERRg is essential in the
oxidative metabolism of the postnatal heart (10).
Published data from various laboratories have shown
that ERRa plays a signiﬁcant role in the regulation of
energy homeostasis. Indeed, ERRa is highly expressed
in tissues with high energy demands such as the heart or
skeletal muscle (11–13). ERRaKO mice display a resis-
tance to diet-induced obesity, altered fat metabolism and
adsorption (14–16), fail to maintain body temperature
when exposed to cold (17) and respond in an altered
manner to cardiac pressure overload (18). These activities
are thought to be exerted mainly in cooperation with
the PPARg coactivator 1-a (PGC1-a), which is instrumen-
tal in many metabolical processes (13,19–20). However,
ERRa is also expressed in many other tissues, in which
its physiological roles has not been determined (11). The
receptor has been proposed to act as a modulator of bone
mass (21), and its high expression in ovarian, colon and
breast cancers correlates with poor prognosis (22–26)
although the functions of ERRa in cancer have not been
investigated.
The structural proximity between ERRs and ERs, in
particular in the DNA-binding domain (DBD) has led
to hypothesis that the ERRs could interfere with the estro-
gen pathway (27). Indeed it has been shown that, at least
in certain cellular and promoter contexts, some
ERR response elements (ERREs) could transduce an
estrogen signal (28–30), as illustrated by the case of the
osteopontin gene promoter (31,32). In addition, such
genes as lactoferrin or the breast cancer marker pS2,
can be coregulated by both ERRa and ERa, through
neighboring sites on their promoter (33,34).
Furthermore, ERRa has been proposed to regulate the
Present addresses:
Catherine Teyssier, Inserm U554, Centre de Biochimie Structurale, Montpellier, France
Olivia Lanvin, Inserm U563, Centre Claudius Re ´ gaud, Toulouse, France
*To whom correspondence should be addressed: Tel: +33 (0) 4 72 72 85 91; Fax: +33 (0) 4 72 72 80 80; Email: Jean-Marc.Vanacker@ens-lyon.fr
 2008 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/
by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.expression of aromatase (35), the rate-limiting enzyme in
estrogen biosynthesis, and the expression of ERRa itself
is reportedly induced by estrogens in the mouse uterus
(36). Phylogenetical studies have grouped the ERRs
in nuclear receptor subfamily 3, not only together with
the ERs but also with the other steroid receptors [StRs,
namely androgen receptor (AR), progesterone receptor
(PR), glucocorticoid receptor (GR) and mineralocorticoid
receptor (MR)] (37). This raises the hypo thesis that ERRs
can also interfere with steroid signaling.
In this report, we show that the expression of androgen-
responsive genes can be down-regulated by the
ERRa-speciﬁc inverse agonist XCT790 in LNCaP
(androgen-dependent human prostate cancer) cells.
Importantly this eﬀect of XCT790 is not exerted through
a modulation of AR expression or activity. ERRa stimu-
lates the activity of androgen-responsive element (ARE)-
containing promoters, including that of PSA, a marker of
prostate cancers. Other steroid-response elements (StRE)-
containing promoters can also be activated by ERRs even
in the presence of antisteroid compounds. Our results thus
document a new level of interferences of ERRs in hormo-
nal pathway.
MATERIALS AND METHODS
Plasmids
ERRa mutants have been described elsewhere (38). For
construction of LEF-RE-Luc reporter plasmid, an oligo-
nucleotide (sequence: 50-GATCCGCACCCTTTGAAGC
TCA-30) encompassing the cognate sequence was cloned
as a trimer in plasmid pGL3-promoter (Promega,
Charbonnie ` res, France) and the construct was veriﬁed
by sequencing. The following plasmids were gifts: PSA
promoter derivatives (HW Chen, UC Davis; described in
ref. 39), scARE2.1-Luc (F Claessens, Leuven University),
DR1-Luc (H Escriva-Garcia, Banyuls-sur-Mer), PGC1-a
(A Kralli, Scripps Institute, San Diego), ARR2PB-Luc (RJ
Matusik, Vanderbilt University; described in ref. 40),
SRC1 (MG Parker, Imperial College, London), GRIP1,
GalAR-AF1, GalAR-LBD (MR Stallcup, USC Los
Angeles; ref 41), pS2-Luc (V. Cavaille ` s, Montpellier),
PerRE-Luc (G. Triqueneaux, ENS Lyon), MMTV-Luc,
GR, DNA-binding deﬁcient GR mutant (GRdim) (42),
AR, ARE-Luc and GRE-Luc (M. Resche-Rigon,
Prostrakan, Romainville). ARE-Luc contains a trimer of
the ARE from the rat probasin promoter (sequence: 50-AG
CTTAATAGGTTCTTGGAGTACTTTACGTCGA-30,
consensus ARE underlined; ref. 43) cloned in front of the
collagenase promoter, scARE2.1 contains four copies of an
ARE (sequence: 50-GGCTCTTTCAGTTCT-30, ARE
underlined; ref. 44) from the secretory component gene
cloned in front of the minimal tk promoter). GRE-Luc
contains an hexamer of the glucocorticoid response ele-
ments (GRE) from the metallothionein promoter
(sequence: 50-CGGTACAAAATGTTCTGGGCC-30, con-
sensus GRE underlined; ref. 45) cloned in front of the
minimal early SV40 promoter.
Cells and transfections
LNCaP cells were cultured in RPMI1640 medium supple-
mented with 10% fetal calf serum, 10mM Hepes and
1mM sodium pyruvate. HeLa and PC3 cells were cultured
in DMEM medium supplemented with 10% fetal calf
serum. For transient transfections 10
5 cells were seeded
in 24-well plates and transfected using 3ml of ExGen
500 (Euromedex, Souﬀelweyersheim, France), 50ng
Luciferase reporter plasmid. CMV-bGal plasmid (50ng)
was added to normalize transfection eﬃciency and pSG5
plasmid was added as a carrier up to 500ng. Cells were
lyzed 48h after transfection and reporter activities were
determined, using standard methods. All transfections
were performed in triplicate. Dexamethasone (Dex),
RU486, dihydrotestosterone (DHT), trichostatin A
(TSA), ﬂutamide and XCT790 were purchased from
Sigma Aldrich (St Quentin Falavier, France) and resus-
pended in DMSO.
The sequences of the siRNAs used to target ERRa are as
follow: sense 50-GGCAGAAACCUAUCUCAGGUU-30,
antisense 50-CCUGAGAUAGGUUUCUGCCUC-30.
The siRNA control was provided by Dharmacon
(siCONTROL Non-Targeting siRNA #1). Annealed
siRNAs were transfected with Lipofectamine 2000
(Invitrogen, Cergy Pontoise, France) into LNCaP cells in
6-well plates ﬁrst for 48h. Cells were transfected a second
time with siRNAs and then treated for 48h with XCT790.
RNA extraction was performed and mRNA levels for the
indicated genes were determined by quantitative PCR
(QPCR) and normalized to the 36B4 mRNA level.
Parallel cell extracts were prepared for immunoblots.
Expression analysis
RNAs were puriﬁed using Guanidinium thiocyanate/
phenol/chloroform extraction. Two micrograms total
RNA were DNaseI-digested and retrotranscribed in a
ﬁnal volume of 20ml using SuperScript II retrotranscrip-
tion kit (InVitrogen, Cergy-Pontoise, France) under the
conditions recommended by the supplier. QPCR were per-
formed using the Sybr Green Jump Start kit (Sigma
Aldrich) in duplicate on a ABI apparatus using standard
PCR cycle. Speciﬁc primers for MAK and KLK2 were
from refs (46) and (47), respectively.
Primers used in this study:
36B4 50-GTCACTGTGCCAGCCCAGAA-3’ and 50-T
CAATGGTGCCCCTGGAGAT-30; AR 50-CCTGGCTT
CCGCAACTTACAC-30 and 50-GGACTTGTGCATG
CGGTACTCA-30; ERR  50-CAAGCGCCTCTGCCTG
GTCT-30 and 50-ACTCGATGCTCCCCTGGATG-30;
KLK2 50-CATCCAGTCTCGGATTG-30 and 50-CTCA
TATTGTAGAGCGGGT-30; MAK 50-GGTCACAGC
CACCATACACTGA-30 and 50-ACTTCCAACAGCCC
ACACATC-30; MAO-A 50-ACCAAGCCAGATGGGT
CA-30 and 50-TTTCCGGGCAAGAATGAA-30; MCAD
50-ATTGGTGACGGAGCTGGTTT-30 and 50-TCCAA
CAGCACCAGCAGCTA-30; NKX3.1 50-GCCGAGAC
GCTGGCAGA-30 and 50-CAGATAAGACCCCAAGT
GCCTTT-30; PGC1-  50-TGGTGCAGTGACCAATCA
GAAA-30 and 50-GGACTGCTAGCAAGTTTGCCTC-
30; PSA 50-ACCAGAGGAGTTCTTGACCCCAAA-30
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AGTTCCACTCAGCCCAGCA-30 and 50-ACAGCCA
ACGTGCTCAGGGA-30.
Westernblot
Cells were lyszed in RIPA buﬀer (50mM Tris, pH 7.5;
150mM NaCl; EDTA 5mM; 0.5% Nonidet P-40; 0.1%
sodium deoxycholate; 0.1% SDS and a cocktail of pro-
tease inhibitors) then centrifuged 15min at 13200rpm.
After 10min heating in Laemmli’s buﬀer, proteins
(30mg) were resolved on 8% SDS–polyacrylamide gel elec-
trophoresis, blotted onto nitrocellulose membrane
(Amersham Biosciences, Orsay, France) and blocked by
incubation at room temperature for 1h in TBS–Tween
0.1% containing 5% nonfat dry milk. Blots were probed
with various Abs (AR, ERRa and actin) and developed
using an enhanced chemiluminescence detection system
(ECL kit, Amersham Biosciences) with appropriate speci-
ﬁc peroxydase conjugated Abs. Anti-AR and antiactin
antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA) and Sigma
Aldrich, respectively. Anti-ERRa has raised in rabbit,
using a KLH-coupled peptide mapping a region conserved
between mouse and human ERRa, but divergent in other
ERR subfamily member.
ChIP
ChIP assays were performed as described previously (48).
Brieﬂy, LNCaP cells were grown in phenol red-free RPMI
1640 supplemented with 10% dextran/charcoal-stripped
serum in 150mm dishes for 3 days, and then treated
with or without 10 nM DHT for 2h. A small portion of
the crosslinked, sheared chromatin solution was saved as
input DNA, and the remainder was precleared by incubat-
ing with 20ml of preblocked protein A agarose/Salmon
Sperm DNA (Upstate Biotech, Chandlers Ford, UK) for
2h. The precleared chromatin was then immunoprecipi-
tated with 2mg of anti-AR antibody (H-280, Santa Cruz
Biotechnology) or 2mg of anti-ERRa antibody (R&D sys-
tems, Minneapolis, MN, USA) with rotation overnight at
48C. The next day, immunoprecipitated DNAs were
recovered by incubated with 20ml of preblocked protein
A agarose/Salmon Sperm DNA (Upstate Biotech) for 2h.
The immune complexes were eluted from beads with
an elution buﬀer (1% SDS and 0.1M NaHCO3).
Crosslinking was reverse overnight at 658C and DNAs
were puriﬁed using QIAquick column (Qiagen,
Courtabœuf, France). Real-time PCR were performed
using 2ml DNA in duplicate on a ABI apparatus using
standard PCR cycles. Primers used in this study have
been previously described (49). Identical results were
obtained when using our own anti-ERRa antibody.
RESULTS
To determine whether ERRa interacts with steroid signal-
ing, we ﬁrst focus on androgen signaling in LNCaP cells.
These cells were treated with the speciﬁc ERRa inverse
agonist XCT790 for 24h. As judged by QPCR,
this compound reduced the expression of several
androgen-responsive genes [PSA/KLK3, NKX3.1, KLK2
and MAK1; (46,50–52)] nearly as eﬃciently as did ﬂuta-
mide, a speciﬁc antiandrogen (Figure 1A). This eﬀect is
not due to a general aspeciﬁc inhibitory eﬀect of XCT790
since the expression of PGC1-a was not modiﬁed. As con-
trols, the expression of ERRa validated target genes, such
as MAO-A, MCAD and RIP140 (6,14,53) were also down-
regulated by XCT790 in LNCaP cells (Figure 1B). No
synergy was observed between ﬂutamide and XCT790.
The latter acted in a time- and dose-dependent manner
(Figure 1C and D, respectively) with a half-maximum eﬃ-
ciency on both PSA and MCAD expression of 5 10
 6M,
a concentration which we used hereafter. TSA [a histone
deacetylase (HDAC) inhibitor] induced in an overexpres-
sion of PSA (Figure 1E) as reported (54). Upon cotreat-
ment with TSA and XCT790, PSA expression displayed an
intermediate level, suggesting that the two phenomena are
independent. XCT790 is thus unlikely to induce HDAC
recruitment to the PSA promoter. To assess the speciﬁcity
of XCT790, LNCaP cells were treated with an siRNA
directed against ERRa (siE). This treatment had no eﬀect
on PSA expression, although it eﬃciently down-regulated
the expression of ERRa mRNA and protein (Figure 1F),
suggesting that other factors could compensate for the
absence of ERRa. However, XCT790 had no eﬀect on
PSA expression when used on siE-treated cells, indicating
that the drug absolutely required ERRa to inhibit PSA
expression.
We next address whether ERRa could transcriptionally
act on the PSA promoter. To this end, we cotransfected
HeLa cells that were chosen because they do not express
PSA. Full-length PSA promoter was activated by ERRa
and by AR (the latter, but not the former, requiring DHT,
as expected) (Figure 2A). A deletion construct in which
the 50 enhancer was absent displayed a reduced response
to AR as published (46), and did not react at all to ERRa,
suggesting that the deleted 50 region could be involved in
the response to both AR and ERRa. As expected, activa-
tion of the PSA promoter by ERRa was inhibited by
XCT790 treatment (Figure 2B). To determine whether
ERRa bound to the endogenous PSA gene, we performed
chromatin immunoprecipitation (ChIP) experiments fol-
lowed by QPCR targeting speciﬁc regions of the PSA pro-
moter (Figure 2C). ERRa was recruited to the enhancer
(Enh) region to a low level, but not to the intermediate
(E–P) or promoter (P) regions. Interestingly XCT790, but
not DHT, signiﬁcantly enhanced the recruitment of the
receptor speciﬁcally to the Enh region. Altogether, this
indicates that ERRa transcriptionally activates the expres-
sion of PSA by binding to its Enh region. XCT790
enhances the binding of the receptor and suppresses its
activity.
TheaboveresultssuggestthatERRacouldactivatetran-
scription through AREs, several copies of which are pre-
sentinthePSAEnhregion.Totestthis hypothesis,weused
other plasmid constructions in which AREs were present in
variousconﬁgurations.Acompositeratprobasinpromoter
derivative(ARR2PB;40)wasactivatedbyERRainadose-
dependent manner without exogenously added DHT
(Figure 3A). In contrast to ERRa, AR achieved a maximal
activation level only in the presence of DHT. ERRa also
5352 Nucleic Acids Research, 2008, Vol. 36, No. 16Figure 1. XCT790 regulates the expression of androgen-responsive genes in LNCaP cells in an ERRa-dependent manner. (A) Cells were treated for
24h with 5 10
 6M XCT790, 10
 6M ﬂutamide or a combination of both, as indicated. RNA were extracted, retrotranscribed and analyzed by
QPCR. Expressions were normalized against 36B4 level and expressed relative to untreated control (C) arbitrarily assigned to 1. Results represent the
average of a typical triplicate experiment with standard deviation as error bar. Experiments were performed at least three times. (B) Same as in (A)
using XCT790 treatment only. (C) Cells were treated with 5 10
 6M XCT790 for the indicated time. PSA and NKX3.1 expression were analyzed as
in (A). (D) Cells were treated with the indicated XCT790 concentrations for 24h. PSA and MCAD mRNA expression were analyzed as in (A).
Results are depicted with a logarithmic scale. (E) Cells were treated with XCT790, TSA (125ng/ml) or both for 72h, with medium renewal every
24h. PSA was analyzed as in (A). (F) Cells in 6-well plate (triplicate) were transfected with 25 pmol/well of ERRa-directed (siE) or unrelated control
(siC) siRNA as described in Materials and methods section and treated or not with XCT790 for 48h. PSA and ERRa mRNA expression were
analyzed as in (A). Protein levels were determined by immunoblots from cell extracts of a fourth siRNA-transfected well. Protein results are from a
single experiment that is representative of three independent ones. mRNA results are the average of three experiments with error bars indicating
standard deviation. ANOVA tests were performed to determine statistical signiﬁcance; ns: nonsigniﬁcant,
  P<0.01.
Nucleic Acids Research, 2008, Vol. 36, No. 16 5353activated transcription from a construct (ARE-Luc)
encompassing three androgen response elements (ARE)
cloned in front of the minimal collagenase promoter
(Figure 3B). DHT supplementation resulted in an additive
eﬀect, due to the endogenous expression of AR in HeLa
cells (as veriﬁed by western blot; data not shown).
Importantly ERRa activated transcription even in the
presence of the antiandrogen ﬂutamide. As expected,
AR activated transcription from the ARE-containing
plasmid, an eﬀect that was maximal upon DHT
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5354 Nucleic Acids Research, 2008, Vol. 36, No. 16supplementation and blunted by ﬂutamide addition.
Altogether, this indicates that an ARE is suﬃcient to
confer ERRa response to a heterologous promoter.
Regulation through AREs was also extended to other
members of the ERR subfamily (Figure 3C). Indeed,
mouse ERRb and g, as well as zebra ﬁsh ERRa-activated
transcription of the synthetic ARE-containing promoter.
PSA promoter was also activated by mouse ERRb and
zebra ﬁsh, but apparently not by mouse ERRg. Some
nuclearreceptorsdisplaytwotranscriptionactivationfunc-
tions, one (the AF1) located in the A/B (N-terminal)
domain and the other (the AF2) located in the extreme C-
terminal part of the molecule. On both reporter constructs,
identical eﬀects were observed using the wild-type or an A/
B domain-deleted version of ERRa. In contrast, this recep-
tor was inactive in the absence of the AF2 function. Thus,
as for transactivation on other response elements (38),
ERRaonlyrequiresthe AF2functionto activatetranscrip-
tion from the ARE site.
In addition to its direct eﬀect on ERRa, XCT790 could
act on PSA expression by regulating the expression and/or
activity of AR, a hypothesis that we next evaluated.
The expression of AR-corresponding mRNA was
unaﬀected by treatment with XCT790, ﬂutamide or a
combination of both (Figure 4A). Likewise, AR protein
level was not reduced upon drug treatment even after a
72h exposure. In contrast, XCT790 dramatically reduced
the ERRa protein level, but not of the corresponding
mRNA, a phenomenon that we also have observed in
several other cell lines (7). We next addressed whether
XCT790 reduced the expression of androgen-responsive
genes by merely blocking AR activity. ChIP experiments
were ﬁrst performed to determine whether AR recruitment
to regions of the PSA promoter was modiﬁed by XCT790
treatment (Figure 4B). As expected, AR bound to the
Enh-, as well as to the P- (although to a lower extent),
but not to the E–P region of the PSA gene, in a DHT-
dependent manner (49). Cotreatment by XCT790 had no
eﬀect on the recruitment of AR to the PSA promoter. We
then reasoned that if XCT790 blocked AR activity on the
PSA promoter, then DHT would be unable to up-regulate
gene expression upon XCT790 pretreatment. On the con-
trary, DHT relieved the inhibition of PSA expression
exerted by XCT790 (Figure 4C). Importantly DHT acti-
vates PSA expression to a similar extent in the presence or
absence of XCT790 (round 2.5-fold). We thus concluded
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Nucleic Acids Research, 2008, Vol. 36, No. 16 5355that XCT790 does not impact on AR expression or
signaling.
ERRa activates transcription through AREs in HeLa
and LNCaP cells, which both express AR. It is thus possi-
ble that AR is required for this eﬀect of ERRa. To address
this hypothesis, we performed cotransfection experiments
in PC3 cells, which do not express AR (Figure 5A). In these
cells, ERRa rather repressed the expression driven by the
PSA promoter. In contrast, upon AR cotransfection,
ERRa activated the PSA promoter in a dose-dependent
manner. Strikingly, DHT was required for the transactiva-
tion by AR, but not for AR to complement ERRa activity.
The same phenomenon was observed using the ARE-Luc
construct. These results indicate that ERRa requires AR to
activate transcription through ARE. In contrast, AR did
not contribute to activation by ERRa of the pS2 promoter
(which does not respond to AR), indicating a speciﬁc eﬀect
on androgen-responsive promoters. We next tried to deter-
mine the domains of AR involved in helping ERRa activa-
tion. Chimerae containing the AR-AF1 or -LBD fused to
the Gal4 DBD did not complement ERRa activity on the
PSA promoter indicating that these AR domains are not
suﬃcient for complementation. We then compared the
eﬀect of GR derivatives. Cotransfection of wild-type GR
resulted in activation of the PSA promoter by ERRa.I n
contrast, GRdim which is defective in DNA binding (42),
did not complement ERRa. This suggests that the DBD of
StRs is necessary to complement ERRa-driven ARE
transactivation.
In an eﬀort to extend our ﬁndings to other steroid
response elements, we next used the MMTV promoter, a
well known model of steroid response. Upon cotransfec-
tion, ERRa by itself was inactive (Figure 6A). However,
when supplemented with the PGC1-a coactivator, ERRa
exerted a dose-dependent activation. The same proﬁle was
also observed using a construct in which GRE from the
metallothionein promoter were cloned in front of the mini-
mal SV promoter. In contrast, constructs harboring multi-
mers of diﬀerent steroid-unrelated response elements
(LEF-RE, responding to TCF/LEF; DR1-Luc, responding
toRAR-RXR; PerRE-Luc, responding toPeriod) were not
activated by ERRa alone or in combination with PGC1-a
(Figure6Aanddatanotshown),indicatingthattheeﬀectis
GRE speciﬁc. Activation is also ERRa speciﬁc, since both
MMTV and GRE-Luc constructs were unable to respond
to ERa, although the latter receptor was active on an estro-
gen response elements-containing plasmid (Figure 6A and
data not shown). However, PGC1-a is not speciﬁc for
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SRC1 or GRIP1/TIF2 resulted in the same eﬀect
(Figure 5B).
Per deﬁnition, transcription from a GRE can be acti-
vated by the GR in the presence of glucocorticoids
(such as the synthetic drug Dex), an eﬀect that can be
abrogated by the addition of synthetic antisteroid com-
pounds such as RU486 (Figure 7A). In contrast, ERRa-
PGC1-a activation through the GRE was unaﬀected by
the presence of both Dex and RU486. This indicates that
ERRa can activate transcription even in the presence of
antisteroid compounds. In addition this also demonstrates
that the eﬀect of ERRa on the GRE does not result from
activation of an endogenous StR, which would be blocked
by RU486. In the experiments above, we observed that
PGC1-a was capable of activating transcription through
the GRE when transfected alone, and not only in the
presence of exogenous ERRa. It is likely that, for this
activity, PGC1-a requires a transcription factor as a
DNA-tethering factor. To determine the nature of this
factor, cells were transfected with GRE-Luc construct
together with varying amounts of PGC1-a and subse-
quently treated with synthetic compounds (Figure 7B).
The activity of PGC1-a was completely abrogated by
XCT790, but not by RU486 treatment, indicating that it
depends on ERRa and not on an endogenous StR.
However, an enhanced PGC1-a eﬀect was observed
when activating the GR pathway by Dex treatment. This
over-activation could be speciﬁcally reversed when adding
RU486. There again, XCT790 was required to completely
abolish the transcriptional potency of PGC1-a. We thus
concluded that PGC1-a is a promiscuous coactivator that
can act through GR and ERRa. However in the absence
of exogenously added hormones, PGC1-a activity on
GRE is strictly dependent on ERRa.
DISCUSSION
Work by various laboratories including ours has pointed
to several levels of interference between ERRa and estro-
gen signaling (27). For example, the recently determined
in vivo ERRa-binding site (55) can also be used as an
estrogen response element (28–32). In this report, we
show that several genes that can be down-regulated by
antiandrogens in LNCaP cells are also subject to repres-
sion by XCT790, an ERRa inverse agonist. This com-
pound acts in a speciﬁc manner since it does not
deactivate other ERRs, ERa nor AR (this report and
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Nucleic Acids Research, 2008, Vol. 36, No. 16 5357ref. 7). Furthermore, whereas the expression of PSA,
NKX3.1, KLK2 and MAK is down-regulated by
XCT790, such genes as AR, PGC1-  or ERR  itself are
not aﬀected, indicating that the compound is not a general
inhibitor of transcription. The eﬀect of XCT790 is depen-
dent on the presence of ERRa since the drug has no eﬀect
in the absence of the receptor.
Since XCT790 down-regulates the expression of various
genes, we expected that overexpression of ERRa, brought
about by adenoviral vector, would result in the opposite
eﬀect. However, in our hands, PSA, NKX3.1 or KLK2 did
not respond to ERRa overexpression (data not shown).
This can be due to a saturating eﬀect of the endogenous
ERRa protein on the promoters of these genes in LNCaP
cells. Alternatively, a stimulating eﬀect of ERRa could
require the coexpression of a yet unidentiﬁed partner.
Although active when transiently transfected alone, we
also noted that the eﬀect of ERRa on the PSA promoter
is much lower than that of AR, suggesting that the orphan
receptor is a weak activator, or that it lacks the coexpres-
sion of a potentializing partner for a maximal eﬀect. The
identity of this eventual partner is unknown but PGC1-a,
bringing no further activation (data not shown), is not a
likely candidate.
In contrast to this, the eﬀect of ERRa on other than-
ARE StREs, requires the coexpression of a coactivator.
The eﬀect of ERRa on StREs (ARE, GRE or MMTV)
also extends to other members of the ERR subfamily, not
only to all mouse ERR isoform, but also to zebra ﬁsh
ERRa and ERRg as well as to the unique ERR present
in the amphioxus [(56,57); Figure 3C and data not shown].
It is thus likely that regulation through StREs is an ances-
tral property of all ERR receptors.
The regulation of expression exerted by ERRa through
an ARE/StRE is at the promoter level, as evidenced by the
fact thatitcanbe transferredtoaheterologous promoterin
a speciﬁc manner. ERRa-responding ARE/StRE include
derivatives from the PB, MMTV and metallothionein
promoters (Figures 3 and 6) as well as from the
nonpalindromic, AR-selective, GR-unresponsive human
secretory component gene promoter (44) (data not
shown). Given the variety of ARE/StRE used in this
study, it seems likely that ERRa acts through this response
element and not through cryptic ERREs that furthermore
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the culture medium as indicated. All reporter activities in
this ﬁgure were determined and expressed as in Figure 2A.
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However, direct binding of in vitro synthesized ERRa pro-
teins on an ARE/StRE could not be observed in electro-
phoretic mobility shift experiments (data not shown),
suggesting that the receptor may require an additional pro-
tein species to bind to ARE/StRE. The capacity to recog-
nizethese sequences depends ontheP-box ofthe DBD(58–
59). The P-box of ERRa is an ER-type (data not shown)
which confers recognition of EREs but not of StREs.
Consistently, we observed that ERRa was recruited to
the PSA enhancer but to a lower extent than AR.
XCT790 does not only deactivate ERRa but also rather
transforms the receptor into an actively repressing factor.
Two lines of evidence support this hypothesis. First, an siE
does not down-regulate PSA expression, indicating that
XCT790 does more than merely eliminating the receptor.
Second, XCT790 promotes a higher level of ERRa recruit-
ment to the PSA promoter. Although this may appear con-
tradictory with XCT790-induced degradation of ERRa,i t
should be reminded that 17b-estradiol also promotes the
degradation of its cognate receptor and its binding to DNA
(60,61). Furthermore, binding of ERRa on the pS2 promo-
ter in MCF7 cells is not diminished by XCT790 treatment
(data not shown) although this also induces the degrada-
tion of the receptor in these cells (7). Thus the action of
XCT790at the local (promoter) level, as visualized by
ChIP, appears diﬀerent from its global (whole cell) eﬀect
observed by western blot.
Several factors have been identiﬁed that transcription-
ally regulate androgen-responsive genes. In some cases,
this regulation is exerted through perturbation of AR
transcriptional activities. This is for instance the case of
C/EBPa and Ebp1 that act as AR corepressors (62,63). In
addition, Ebp1 also down-regulates the expression of AR
itself providing an additional indirect control level on the
expression of AR-dependent genes (47). None of these
mechanisms are likely to explain the eﬀects of the ERRa
inverse agonist. Indeed, this compound does not pertur-
bate AR expression or activity. This suggests that AR and
ERRa act in parallel pathways. However, we did not
observe any additive eﬀect of antiandrogen and anti-
ERRa cotreatment, which suggests that both drugs even-
tually act on a common factor. This apparent discrepancy
can be solved when hypothesizing that ERRa requires AR
to act on androgen-responsive promoter. In support
to this, we observed that ERRa was capable of activating
the PSA promoter in PC3 cells (which do not express AR)
only upon AR supplementation. However, it should be
noted that an active conformation of AR is not an abso-
lute requirement. Indeed, ERRa transactivates through
the ARE in the presence of the antiandrogen ﬂutamide
in PC3 as well as in HeLa cells (Figure 3B and data not
shown). In PC3 cells, ERRa can also be complemented by
GR to activate the PSA promoter. Interestingly, GRdim is
inactive in ERRa complementation, indicating that DNA
binding by a StR is involved. Consistenly, (i) the AF1 or
LBD moiety of AR are not suﬃcient to promote ERRa
activity on the PSA promoter, (ii) ERRa does not pro-
mote the activity of GalAR-AF1 or GalAR-LBD on
Gal4-binding sites (data not shown). Altogether, this sug-
gests that ERRa does not directly bind to the ARE but
establishes transient contacts with a DNA-bound StR.
XCT790 stabilizes these contacts and also induces a
repressing conformation of ERRa, leading to promoter
repression. Interestingly, this is unlikely to be mediated
by HDAC recruitment.
Androgens play an essential role in prostate physiology.
Prostate cancers are androgen-dependent for their growth,
at least in the initial phases of the disease (64,65).
Antiandrogen-based therapies are therefore widely used
in the treatment of prostate tumors. Unfortunately,
these tumors eventually develop resistance to antiandro-
gens, a phenomenon that lead to poor prognosis. Our
results show that ERRa is able to stimulate the expression
of androgen-responsive genes, even in the presence of anti-
androgen. Our data may thus suggest that ERRa over-
expression could help the cells to bypass the block
exerted by antiandrogens. Through this, ERRa could
play a role in the acquisition of androgen resistance in
advanced prostate tumors. It has been shown that
ERRa is indeed expressed in the prostate and in human
prostatic cell lines (66). An eventual link between resis-
tance to antiandrogen therapy and ERRa expression has
not yet been investigated, but it should be noted that high
ERRa expression is associated to poor prognosis in ovar-
ian, breast and colon tumors (22–26). ERRa is active on
ARE/StRE-containing promoters in the presence of the
antisteroid synthetic compounds RU486 and ﬂutamide.
Our results lead to the hypothesis that a complete repres-
sion of such genes not only requires to inactivate the StRs
but also the ERR family members.
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